Unicycive Therapeutics (UNCY) Price & Analysis

Compare

709 Followers

UNCY Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.41 - $11.00

Previous CloseN/A

Volume1.16M

Average Volume (3M)494.91K

Market Cap

$69.94M

Enterprise Value$36.76M

Total Cash (Recent Filing)$22.33M

Total Debt (Recent Filing)$476.00K

Price to Earnings (P/E)―

Beta1.46

Next Earnings

Nov 18, 2025

EPS Estimate

-0.63

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding17,661,697

10 Day Avg. Volume520,938

30 Day Avg. Volume494,908

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.53

Enterprise Value/Revenue64.72

Enterprise Value/Gross Profit-328.24

Enterprise Value/Ebitda-0.93

Forecast

1Y Price Target

$16.50

Price Target Upside316.67% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial StabilityUnicycive’s current cash remains sufficient to sustain operations into the second half of 2026.

Product DevelopmentOLC's nanoparticle formulation allows for a swallowable, non-chewable tablet with fewer, smaller pills per dose.

Regulatory ApprovalThere are no concerns with the drug’s safety or efficacy, leading to a positive outlook on OLC eventually receiving approval for the treatment of hyperphosphatemia following a delay.

Bears Say

Manufacturing ChallengesManagement has identified a second vendor that has produced OLC and plans to seek a Type A meeting with the FDA.

Regulatory SetbacksThe CRL was based on deficiencies following cGMP inspection of a third-party manufacturing vendor, with no issues raised relating to the preclinical, clinical, or safety aspects of the drug.

Unicycive Therapeutics News

Unicycive Therapeutics price target adjusted at Benchmark after reverse split

Benchmark raised the firm’s price target on Unicycive Therapeutics (UNCY) to $21 from $3 and keeps a Speculative...

7d ago

UNCY

Unicycive Faces Class Action Over FDA Misleading Claims

Unicycive Therapeutics, Inc., a biopharmaceutical company, is facing a class action lawsuit that could have significant implications for...

1M ago

UNCY

Unicycive Faces Securities Lawsuit Over Drug Claims

Unicycive Therapeutics ( ($UNCY) ) has provided an update. On August 15, 2025, Unicycive Therapeutics was named in...

1M ago

UNCY

Unicycive Therapeutics granted new U.S. patent for UNI-494 to treat CKD

Unicycive Therapeutics (UNCY) announced the issuance of U.S. Patent 12,377,082 by the U.S. Patent and Trademark Office for...

1M ago

UNCY

Unicycive Therapeutics Raises $16.3 Million in Stock Sale

Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. Unicycive Therapeutics, Inc. sold 3,549,846 shares of common stock...

1M ago

UNCY

Unicycive Therapeutics: Buy Rating Amid FDA Compliance Resolution and Strong Financial Position

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics, retaining the price target of...

1M ago

UNCY

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

“Our team has made great progress in the second quarter, and we have requested a Type A meeting...

1M ago

UNCY

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

Unicycive has requested a Type A meeting with the FDA to discuss resolution of the CRL received in...

1M ago

UNCY

Unicycive Therapeutics expects cash to fund operations into 2H of 2026

As of June 30, 2025, cash and cash equivalents totaled $22.3 million. The Company believes that it has...

1M ago

UNCY

Unicycive Therapeutics announces publication of OLC trial data

Unicycive Therapeutics (UNCY) announced the publication of trial data describing the safety and tolerability of oxylanthanum carbonate, OLC,...

2M ago

UNCY

Unicycive Regains Nasdaq Compliance After Stock Split

Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. On July 8, 2025, Unicycive Therapeutics announced it regained...

3M ago

UNCY

Unicycive Therapeutics regains compliance with Nasdaq bid price requirement

Unicycive Therapeutics (UNCY) has regained compliance with Nasdaq continued listing standard for minimum share price. On July 7,...

3M ago

UNCY

Unicycive Therapeutics approval delay ‘not a surprise,’ says Noble Capital

The receipt of a Complete Response Letter in response to Unicycive’s New Drug Application for Oxylanthanum Carbonate was...

3M ago

UNCY

Unicycive Receives FDA CRL for New Drug Application

An update from Unicycive Therapeutics ( ($UNCY) ) is now available. On June 30, 2025, Unicycive Therapeutics announced...

3M ago

UNCY

UNCY FAQ

What was Unicycive Therapeutics’s price range in the past 12 months?

Unicycive Therapeutics lowest stock price was $3.41 and its highest was $11.00 in the past 12 months.

What is Unicycive Therapeutics’s market cap?

Unicycive Therapeutics’s market cap is $69.94M.

When is Unicycive Therapeutics’s upcoming earnings report date?

Unicycive Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 57 days.

How were Unicycive Therapeutics’s earnings last quarter?

Unicycive Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.683 by $0.163.

Is Unicycive Therapeutics overvalued?

According to Wall Street analysts Unicycive Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Unicycive Therapeutics pay dividends?

Unicycive Therapeutics does not currently pay dividends.

What is Unicycive Therapeutics’s EPS estimate?

Unicycive Therapeutics’s EPS estimate is -0.63.

How many shares outstanding does Unicycive Therapeutics have?

Unicycive Therapeutics has 17,661,697 shares outstanding.

What happened to Unicycive Therapeutics’s price movement after its last earnings report?

Unicycive Therapeutics reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.683. Following the earnings report the stock price went up 4.989%.

Which hedge fund is a major shareholder of Unicycive Therapeutics?

Among the largest hedge funds holding Unicycive Therapeutics’s share is RA Capital Management. It holds Unicycive Therapeutics’s shares valued at 0.

Unicycive Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-3987.11%

Trailing 12-Months

Asset Growth

-32.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Unicycive Therapeutics

Unicycive Therapeutics (UNCY) is a biopharmaceutical company focused on developing novel treatments for kidney diseases. The company operates within the healthcare sector, specifically targeting nephrology. Its core products include innovative therapies aimed at addressing unmet medical needs in patients suffering from chronic kidney diseases and related conditions.

Unicycive Therapeutics (UNCY) Earnings & Revenues

Historic Earnings Reports

UNCY Stock 12 Month Forecast

Average Price Target

$16.50

▲(316.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,6.295384615384616,8.27076923076923,10.246153846153845,12.221538461538461,14.196923076923078,16.17230769230769,18.147692307692306,20.123076923076923,22.09846153846154,24.073846153846155,26.049230769230768,28.024615384615384,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,5.256923076923077,6.193846153846154,7.13076923076923,8.067692307692308,9.004615384615384,9.94153846153846,10.878461538461538,11.815384615384616,12.752307692307692,13.689230769230768,14.626153846153846,15.563076923076922,{"y":16.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.32,4.44923076923077,4.578461538461538,4.707692307692308,4.836923076923077,4.966153846153846,5.095384615384615,5.224615384615385,5.353846153846154,5.483076923076923,5.612307692307692,5.741538461538461,5.8707692307692305,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.14,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >